- Home
- JKS vs AGIO Comparison
JKS vs AGIO Comparison
Compare JKS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKS
- AGIO
- Stock Information
- Founded
- JKS 2006
- AGIO 2007
- Country
- JKS China
- AGIO United States
- Employees
- JKS N/A
- AGIO N/A
- Industry
- JKS Semiconductors
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- JKS Technology
- AGIO Health Care
- Exchange
- JKS Nasdaq
- AGIO Nasdaq
- Market Cap
- JKS 1.3B
- AGIO 1.4B
- IPO Year
- JKS 2010
- AGIO 2013
- Fundamental
- Price
- JKS $24.00
- AGIO $38.79
- Analyst Decision
- JKS Hold
- AGIO Buy
- Analyst Count
- JKS 5
- AGIO 6
- Target Price
- JKS $27.19
- AGIO $58.60
- AVG Volume (30 Days)
- JKS 989.2K
- AGIO 629.3K
- Earning Date
- JKS 08-29-2025
- AGIO 07-31-2025
- Dividend Yield
- JKS 6.18%
- AGIO N/A
- EPS Growth
- JKS N/A
- AGIO N/A
- EPS
- JKS N/A
- AGIO 11.45
- Revenue
- JKS $11,445,691,729.00
- AGIO $37,035,000.00
- Revenue This Year
- JKS N/A
- AGIO $22.30
- Revenue Next Year
- JKS $36.29
- AGIO $219.19
- P/E Ratio
- JKS N/A
- AGIO $3.43
- Revenue Growth
- JKS N/A
- AGIO 25.96
- 52 Week Low
- JKS $13.42
- AGIO $23.42
- 52 Week High
- JKS $37.36
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- JKS 70.79
- AGIO 71.92
- Support Level
- JKS $23.71
- AGIO $34.60
- Resistance Level
- JKS $24.81
- AGIO $40.06
- Average True Range (ATR)
- JKS 1.17
- AGIO 1.42
- MACD
- JKS 0.14
- AGIO 0.42
- Stochastic Oscillator
- JKS 77.27
- AGIO 95.62
About JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.